HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gang Niu Selected Research

Antigens

1/2023FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
1/2019In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy.
1/2018Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker.
1/2018Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG.
1/2018Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors.
1/2017Efficient Nanovaccine Delivery in Cancer Immunotherapy.
7/2012Molecular targeting of CEACAM6 using antibody probes of different sizes.
10/2011Imaging tumor endothelial marker 8 using an 18F-labeled peptide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gang Niu Research Topics

Disease

196Neoplasms (Cancer)
01/2024 - 03/2004
23Breast Neoplasms (Breast Cancer)
01/2021 - 08/2008
21Neoplasm Metastasis (Metastasis)
01/2024 - 10/2008
12Prostatic Neoplasms (Prostate Cancer)
01/2023 - 03/2008
9Ovarian Neoplasms (Ovarian Cancer)
01/2020 - 09/2009
7Brain Neoplasms (Brain Tumor)
02/2024 - 11/2008
7Inflammation (Inflammations)
04/2020 - 04/2011
7Glioblastoma (Glioblastoma Multiforme)
01/2018 - 08/2008
6Colorectal Neoplasms (Colorectal Cancer)
01/2020 - 11/2008
6Insulinoma
01/2019 - 10/2011
5Body Weight (Weight, Body)
09/2019 - 03/2011
5Squamous Cell Carcinoma of Head and Neck
02/2012 - 03/2004
4Glioma (Gliomas)
09/2018 - 01/2015
4Lymphatic Metastasis
01/2018 - 02/2013
4Insulin Resistance
01/2017 - 06/2009
4Head and Neck Neoplasms (Head and Neck Cancer)
01/2013 - 03/2004
3Infections
04/2024 - 05/2005
3Pain (Aches)
01/2024 - 04/2011
3Lung Neoplasms (Lung Cancer)
02/2023 - 12/2015
3Disease Progression
01/2023 - 10/2011
3Melanoma (Melanoma, Malignant)
01/2020 - 10/2011
3Hyperthermia
01/2019 - 01/2017
3Neuroendocrine Tumors (Neuroendocrine Tumor)
11/2018 - 10/2015
3Type 2 Diabetes Mellitus (MODY)
11/2017 - 09/2005
3Hepatocellular Carcinoma (Hepatoma)
11/2017 - 10/2015
3Carcinoma (Carcinomatosis)
10/2017 - 11/2008
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2017 - 01/2013

Drug/Important Bio-Agent (IBA)

29Peptides (Polypeptides)IBA
01/2020 - 08/2008
25IntegrinsIBA
11/2018 - 05/2007
24Proteins (Proteins, Gene)FDA Link
10/2020 - 10/2008
13Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 01/2011
11Biomarkers (Surrogate Marker)IBA
02/2023 - 01/2008
111,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA
01/2017 - 09/2009
9Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2019 - 01/2009
8AntigensIBA
01/2023 - 10/2011
8GoldIBA
10/2018 - 06/2013
8Glucose (Dextrose)FDA LinkGeneric
11/2017 - 09/2005
71,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
01/2023 - 08/2008
7ErbB Receptors (EGF Receptor)IBA
04/2019 - 03/2008
7AcidsIBA
01/2019 - 08/2008
7AlbuminsIBA
01/2019 - 07/2014
7arginyl-glycyl-aspartic acidIBA
08/2014 - 05/2007
61-phenyl-3,3-dimethyltriazene (PDT)IBA
11/2020 - 02/2015
6LigandsIBA
05/2019 - 01/2011
6Exenatide (Byetta)FDA Link
01/2019 - 01/2012
6Messenger RNA (mRNA)IBA
12/2018 - 12/2012
6Bombesin Receptors (Bombesin Receptor)IBA
01/2018 - 09/2009
6Matrix Metalloproteinases (MMPs)IBA
11/2014 - 06/2011
5Small Interfering RNA (siRNA)IBA
01/2024 - 10/2011
5Coloring Agents (Dyes)IBA
03/2020 - 03/2011
5Photosensitizing Agents (Photosensitizers)IBA
01/2020 - 06/2013
5ProdrugsIBA
03/2019 - 01/2017
5Contrast MediaIBA
01/2019 - 09/2009
5Ferritins (Ferritin)IBA
01/2018 - 02/2011
5Radioisotopes (Radionuclides)IBA
01/2018 - 01/2008
5Evans Blue (Blue, Evans)FDA Link
01/2018 - 07/2009
5cyclic arginine-glycine-aspartic acid peptideIBA
09/2012 - 06/2009
5Integrin alphaVbeta3IBA
02/2010 - 01/2008
4PolymersIBA
03/2020 - 01/2019
4Reactive Oxygen Species (Oxygen Radicals)IBA
01/2020 - 01/2017
4NanovaccinesIBA
01/2020 - 03/2016
4VaccinesIBA
01/2020 - 01/2017
4Glucagon-Like Peptide-1 ReceptorIBA
01/2019 - 01/2012
4Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
12/2018 - 01/2011
4Estrogen ReceptorsIBA
12/2018 - 03/2016
4alfatide IIIBA
12/2018 - 04/2012
4Gadolinium DTPA (Magnevist)FDA Link
07/2018 - 09/2012
4Silicon Dioxide (Silica)FDA LinkGeneric
01/2018 - 06/2012
4BombesinIBA
01/2018 - 09/2009
4cupric sulfide (CuS)IBA
01/2018 - 01/2014
4Firefly LuciferasesIBA
01/2017 - 05/2007
4Cetuximab (Erbitux)FDA Link
01/2017 - 07/2009
4Chemokine ReceptorsIBA
02/2016 - 01/2012
4graphene oxideIBA
09/2015 - 10/2012
4Glucagon-Like Peptide 1 (GLP 1)IBA
01/2015 - 10/2011
4GlucokinaseIBA
01/2014 - 03/2011
3177Lu-PSMA-617IBA
01/2023 - 01/2019
32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH)IBA
01/2020 - 01/2014
3IonsIBA
10/2019 - 01/2017
3177Lu-EB-PSMA-617IBA
06/2019 - 01/2018
3Glutathione (Reduced Glutathione)IBA
11/2018 - 01/2017
3DNA (Deoxyribonucleic Acid)IBA
03/2018 - 03/2016
3Indicators and Reagents (Reagents)IBA
02/2018 - 08/2011
3Chelating AgentsIBA
01/2018 - 12/2011
3CopperIBA
01/2018 - 03/2016
3Oxygen (Dioxygen)IBA
01/2018 - 01/2017
3Albumin-Bound PaclitaxelFDA Link
12/2017 - 01/2011
3Monoclonal AntibodiesIBA
11/2017 - 11/2008
3LuciferasesIBA
10/2017 - 08/2012

Therapy/Procedure

78Therapeutics
01/2021 - 01/2008
25Precision Medicine
11/2022 - 01/2008
20Drug Therapy (Chemotherapy)
01/2023 - 11/2010
16Intravenous Injections
10/2019 - 03/2011
13Immunotherapy
11/2020 - 04/2010
10Lasers (Laser)
01/2020 - 05/2014
10Photothermal Therapy
12/2018 - 08/2014
8Photochemotherapy (Photodynamic Therapy)
01/2020 - 01/2014
6Radiotherapy
01/2020 - 03/2004
5Aftercare (After-Treatment)
01/2017 - 07/2011
3Castration
01/2023 - 01/2019